Resistance studies with Streptococcus pneumoniae using an in vitro dynamic model: amoxicillin versus azithromycin at
Maria V Golikova1, Elena N Strukova1, Yury A Portnoy1
1Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics , Moscow , Russia.
Abstract:
Current knowledge of the emergence of Streptococcus pneumoniae resistance during treatment with aminopenicillins and macrolides is limited. In particular, clinical reports on isolation of azithromycin-resistant mutants do not relate their enrichment to the actual antibiotic concentrations in blood. In the present work, the selection of amoxicillin- and azithromycin-resistant S. pneumoniae mutants at therapeutic and subtherapeutic antibiotic exposures was studied in an in vitro dynamic model. There was no enrichment of S. pneumoniae mutants resistant to amoxicillin, while azithromycin-resistant mutants were enriched in all simulations. This difference was related to the different times above the mutant prevention concentration: 60-100% of the dosing interval for amoxicillin versus zero percentage for azithromycin. These findings are in concordance with the mutant selection window hypothesis.
Insights
Emergence of Streptococcus pneumoniae resistance to azithromycin, but not amoxicillin, was observed in vitro. This suggests azithromycin resistance may develop more readily under typical dosing conditions compared to amoxicillin.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Limited understanding of Streptococcus pneumoniae resistance development during aminopenicillin and macrolide treatment.
- Lack of correlation between clinical isolation of azithromycin-resistant mutants and actual blood antibiotic concentrations.
Purpose of the Study:
- To investigate the selection of amoxicillin- and azithromycin-resistant S. pneumoniae mutants under therapeutic and subtherapeutic antibiotic exposures.
- To compare the enrichment of resistant mutants in an in vitro dynamic model simulating different antibiotic concentrations.
Main Methods:
- Utilized an in vitro dynamic model to simulate antibiotic exposures.
- Exposed Streptococcus pneumoniae to varying concentrations of amoxicillin and azithromycin.
- Monitored the enrichment of resistant mutants throughout the simulations.
Main Results:
- No enrichment of amoxicillin-resistant S. pneumoniae mutants was observed.
- Azithromycin-resistant S. pneumoniae mutants were enriched in all simulations.
- Differences in resistance selection were linked to time above the mutant prevention concentration (MPC).
Conclusions:
- Findings support the mutant selection window hypothesis.
- Amoxicillin exposure maintained concentrations above the MPC for longer durations, inhibiting resistance.
- Azithromycin exposure frequently fell below the MPC, facilitating the selection of resistant mutants.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Resistivity
Resistance


